These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 14713774)

  • 1. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
    Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
    J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of urinary survivin as a diagnostic marker in bladder cancer.
    Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
    Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine detection of survivin and diagnosis of bladder cancer.
    Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
    JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
    Sun Y; He H; Ma Q; Wang XY; Yang L; He DL
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2507-12. PubMed ID: 16321281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
    JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of urine survivin in 40 patients with bladder cancer.
    Ohsawa I; Nishimura T; Kondo Y; Kimura G; Satoh M; Matsuzawa I; Hamasaki T; Ohta S
    J Nippon Med Sch; 2004 Dec; 71(6):379-83. PubMed ID: 15673958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
    Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
    Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.